Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.79 USD | +0.75% | +16.64% | +4.89% |
May. 10 | Warby Parker Guidance Achievable, Path Still Uncertain, Morgan Stanley Says | MT |
May. 10 | UBS Boosts Price Target on Warby Parker to $15 From $13, Keeps Neutral Rating | MT |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.89% | 1.76B | C+ | ||
+12.13% | 40.03B | B | ||
+0.16% | 18.83B | B- | ||
-14.13% | 2.41B | D+ | ||
+24.59% | 1.19B | - | ||
-34.19% | 765M | - | ||
-35.08% | 745M | B- | ||
-6.50% | 676M | - | ||
+22.63% | 490M | - | - | |
+26.77% | 489M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WRBY Stock
- Ratings Warby Parker Inc.